Popular Trials
Cancer Vaccine
Combination Vaccine for Neuroblastoma
This trial tests a new treatment for high-risk neuroblastoma using two types of cancer cell vaccines. One vaccine is modified to release proteins that boost the immune system. The goal is to help the body fight cancer more effectively.
Monoclonal Antibodies
Immunotherapy for Neuroblastoma
This trial will determine how well autologous expanded natural killer cells work with standard dosing of dinutuximab and with or without lenalidomide in treating children with neuroblastoma that has come back or does not respond to treatment.
Proton Beam Therapy
Proton Radiation Therapy for Neuroblastoma
This trial is looking at proton beam radiation therapy (PBRT) as a possible treatment for neuroblastoma. Neuroblastoma is a cancer that most commonly occurs in and around the adrenal glands, but can also occur in other areas where groups of nerve cells exist. Standard radiation therapy with photons is used as standard treatment for many patients with neuroblastic tumors, but proton radiation is known to spare surrounding tissues and organs from unnecessary radiation. The trial will assess the effectiveness of PBRT in reducing side effects associated with radiation treatment and the late side effects experienced by participants.
Popular Filters
Trials for NBL Patients
Monoclonal Antibodies
Combination Therapy for Neuroblastoma
This trial is testing a new monoclonal antibody (mAb) to see if it is effective in treating neuroblastoma, a cancer that commonly affects children. The mAb targets a protein that is found on the surface of neuroblastoma cells.
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma
This trial involves treating patients with relapsed or refractory neuroblastoma using specially modified immune cells that can better recognize and attack their cancer. These modified cells are supported by chemotherapy and an additional drug to help them work more effectively. The goal is to see if this approach can safely extend the time these cells stay active in the body and improve their ability to fight cancer.
Cancer Vaccine
Tumor Cell Vaccine + Cytoxan for Neuroblastoma
This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.
Cancer Vaccine
Vaccine + Immunological Adjuvant for Neuroblastoma
This trial is testing a bivalent vaccine that has two antigens, GD2L and GD3L. The goal is to see if the patient's immune system can make antibodies against the two antigens, which would then attach to neuroblastoma cells and kill them.
Trials for Cancer Patients
Peptide Receptor Radionuclide Therapy
Peptide Receptor Radionuclide Therapy for Neuroblastoma
This trial is testing a new treatment called 67Cu-SARTATE for children with high-risk neuroblastoma. The treatment uses radiation to target and kill cancer cells. The goal is to see if this approach is safe and effective for these patients.
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Solid Cancers
This trial is testing genetically-modified T cells to treat solid tumors in children and young adults. The goal is to evaluate safety and feasibility, and to determine if the cells can kill tumors.
CAR T-cell Therapy
CAR T Cell Therapy for Pediatric Cancer
This trial tests a new treatment for children and young adults with hard-to-treat solid tumors. It uses the patient's own immune cells, modified to better attack cancer cells. The study aims to see if this approach is safe and effective. This type of therapy has shown remarkable results in young patients with certain types of blood cancers.
Trials for Metastatic Patients
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma
This trial involves treating patients with relapsed or refractory neuroblastoma using specially modified immune cells that can better recognize and attack their cancer. These modified cells are supported by chemotherapy and an additional drug to help them work more effectively. The goal is to see if this approach can safely extend the time these cells stay active in the body and improve their ability to fight cancer.
CAR T-cell Therapy
EBV-specific CTLs for Neuroblastoma
This trial is testing a new way to fight neuroblastoma, a form of cancer, by combining two different types of cells that each attack the disease in different ways. The new cell is made by attaching an antibody that recognizes neuroblastoma cells to a type of cell that normally fights infectious mononucleosis. This new cell is given to patients with neuroblastoma that has returned and is not responding to other treatments.
Multi-kinase inhibitor
Sorafenib + Cyclophosphamide/Topotecan for Neuroblastoma
This trial will test a combination of 3 drugs - sorafenib, cyclophosphamide, and topotecan - to see if it's effective and safe for patients with neuroblastoma that has resisted or returned after treatment.
Trials for MYC Positive Patients
Monoclonal Antibodies
Combination Therapy for Neuroblastoma
This trial is testing a new monoclonal antibody (mAb) to see if it is effective in treating neuroblastoma, a cancer that commonly affects children. The mAb targets a protein that is found on the surface of neuroblastoma cells.
Cancer Vaccine
Vaccine + Immunological Adjuvant for Neuroblastoma
This trial is testing a bivalent vaccine that has two antigens, GD2L and GD3L. The goal is to see if the patient's immune system can make antibodies against the two antigens, which would then attach to neuroblastoma cells and kill them.
Trials With No Placebo
Monoclonal Antibodies
Combination Therapy for Neuroblastoma
This trial is testing a new monoclonal antibody (mAb) to see if it is effective in treating neuroblastoma, a cancer that commonly affects children. The mAb targets a protein that is found on the surface of neuroblastoma cells.
CAR T-cell Therapy
CAR T-Cell Therapy for Neuroblastoma
This trial involves treating patients with relapsed or refractory neuroblastoma using specially modified immune cells that can better recognize and attack their cancer. These modified cells are supported by chemotherapy and an additional drug to help them work more effectively. The goal is to see if this approach can safely extend the time these cells stay active in the body and improve their ability to fight cancer.
Cancer Vaccine
Tumor Cell Vaccine + Cytoxan for Neuroblastoma
This trial is testing an experimental treatment for neuroblastoma, which is a solid tumor that is the second most common cancer in children. The treatment consists of a series of immunizations using a tumor vaccine, combined with low-dose chemotherapy taken by mouth on a daily basis. The hope is that the vaccine will cause the immune system to recognize and kill more types of neuroblastoma tumors. Additionally, the immunizations will be combined with daily low dose chemotherapy.
Cancer Vaccine
Vaccine + Immunological Adjuvant for Neuroblastoma
This trial is testing a bivalent vaccine that has two antigens, GD2L and GD3L. The goal is to see if the patient's immune system can make antibodies against the two antigens, which would then attach to neuroblastoma cells and kill them.
View More Related Trials
Frequently Asked Questions
Introduction to neuroblastoma
What are the top hospitals conducting neuroblastoma research?
When it comes to the fight against neuroblastoma, a rare and aggressive cancer that primarily affects children, several top hospitals across the United States are leading the charge in clinical trials. In Los Angeles, Children's Hospital Los Angeles takes center stage with an impressive 28 ongoing trials focused on neuroblastoma. This renowned institution has been at the forefront of research for this condition since recording its first trial in 1988. Similarly, Cincinnati Children's Hospital Medical Center also boasts 28 active neuroblastoma trials and carries an exceptional track record with a total of 86 completed studies since their first recorded trial in 1988.
Not to be outdone, Memorial Sloan Kettering Cancer Center in New york is making significant contributions as well. With 28 currently active neuroblastoma trials and a solid history of 55 previous studies conducted since initiating their inaugural trial in 1995, they remain dedicated to advancing our understanding and treatment options for this challenging disease.
Meanwhile, Children's Hospital Colorado located in Aurora has emerged as another key player with its commitment to finding innovative solutions through its ongoing participation in twenty-five active neuroblastoma trials while having conducted forty-seven overall studies starting from their initial investigation into these cases back in2000.With consistent pursuit towards medical progress within Kansas City area itself;Children’s Mercy Hospitals & Clinics have not only made valuable contribution by actively partaking25ongoing research projects specifically targeting Neuroblatstomatic conditions but also deserve appreciation for dedicating time to previous four decades long forty investigations covering numerous aspects pertaining such complex ailment ,starting from year2000 onwards
These esteemed hospitals represent hope for families affected by neuroblastoma and exemplify the tireless efforts undertaken by healthcare professionals nationwide. The collective endeavors of these institutions bring us closer to breakthroughs that will improve outcomes for patients battling this devastating disease. Through cutting-edge research and compassionate care, they champion advancements that hold promise for a brighter future in the fight against neuroblastoma.
Which are the best cities for neuroblastoma clinical trials?
When it comes to neuroblastoma clinical trials, several cities have emerged as key hubs for research and innovation. New york City leads the pack with 72 active trials, focusing on a range of treatments including Palbociclib, Selumetinib Sulfate, and others. Following closely behind are Saint Louis in Missouri with 64 ongoing studies exploring options like Palbociclib and Cyclophosphamide, and Orlando in Florida with 61 trials investigating similar interventions. Chicago in Illinois also boasts a significant presence with 53 active trials studying Temozolomide and Autologous Hematopoietic Stem Cell Transplantation among other potential therapies. Finally, Boston in Massachusetts rounds out the top five cities with 48 ongoing studies investigating treatments such as induction therapy, consolidation therapy, ASCT (autologous stem cell transplantation), and more. These cities offer individuals battling neuroblastoma access to cutting-edge clinical trials that give hope for improved outcomes through innovative approaches to treatment.
Which are the top treatments for neuroblastoma being explored in clinical trials?
Cutting-edge research in the fight against neuroblastoma has identified several promising treatments currently under exploration in clinical trials. Leading the pack is a pharmacological study, with four active trials and 16 all-time neuroblastoma trials since its initial listing in 2001. DFMO, another notable contender, shines brightly with three ongoing trials and six all-time neuroblastoma studies since its introduction in 2010. Also showing great potential is 131I-MIBG, which joins the race boasting two active and five all-time neuroblastoma trials following its first appearance on the scene in 2005. Rounding out this impressive lineup is nivolumab, gaining traction with two active and six all-time neuroblastoma trials after making waves upon its arrival in 2015. With each trial comes renewed hope for finding effective treatments for those facing this challenging disease.
What are the most recent clinical trials for neuroblastoma?
Recent clinical trials offer promising prospects for the treatment of neuroblastoma, a challenging pediatric cancer. One notable trial investigates the combination of ex vivo expanded allogeneic γδ T cells with dinutuximab, temozolomide, irinotecan, and zoledronate. In another study, researchers are exploring an innovative approach using anti-CD30 bispecific antibody-armed anti-CD3-activated autologous T-cells (CD30 biAb-AATC). These trials aim to evaluate their effectiveness in improving outcomes for patients with neuroblastoma. While still in early phases, these advancements hold great potential for enhancing therapeutic options and ultimately improving survival rates for those battling this aggressive disease.
What neuroblastoma clinical trials were recently completed?
A recent completion of a clinical trial for neuroblastoma involved the investigation of chemotherapy and was sponsored by AbbVie. This trial concluded in November 2017, providing valuable insights into the efficacy and safety of this treatment approach. The findings from this study contribute to our understanding of how chemotherapy can be utilized in combating neuroblastoma, offering potential avenues for improved patient outcomes.